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Background: Human tumour xenografts in immune compromised mice are widely used as cancer models because
they are easy to reproduce and simple to use in a variety of pre-clinical assessments. Developments in
nanomedicine have led to the use of tumour xenografts in testing nanoscale delivery devices, such as nanoparticles
and polymer-drug conjugates, for targeting and efficacy via the enhanced permeability and retention (EPR) effect.
For these results to be meaningful, the hyperpermeable vasculature and reduced lymphatic drainage associated
with tumour pathophysiology must be replicated in the model. In pre-clinical breast cancer xenograft models, cells
are commonly introduced via injection either orthotopically (mammary fat pad, MFP) or ectopically (subcutaneous,
SC), and the organ environment experienced by the tumour cells has been shown to influence their behaviour.
Methods: To evaluate xenograft models of breast cancer in the context of EPR, both orthotopic MFP and ectopic
SC injections of MDA-MB-231-H2N cells were given to NOD scid gamma (NSG) mice. Animals with matched
tumours in two size categories were tested by injection of a high molecular weight dextran as a model nanocarrier.
Tumours were collected and sectioned to assess dextran accumulation compared to liver tissue as a positive
control. To understand the cellular basis of these observations, tumour sections were also immunostained for
endothelial cells, basement membranes, pericytes, and lymphatic vessels.
Results: SC tumours required longer development times to become size matched to MFP tumours, and also
presented wide size variability and ulcerated skin lesions 6 weeks after cell injection. The 3 week MFP tumour
model demonstrated greater dextran accumulation than the size matched 5 week SC tumour model (for P < 0.10).
Immunostaining revealed greater vascular density and thinner basement membranes in the MFP tumour model
3 weeks after cell injection. Both the MFP and SC tumours showed evidence of insufficient lymphatic drainage, as
many fluid-filled and collagen IV-lined spaces were observed, which likely contain excess interstitial fluid.
Conclusions: Dextran accumulation and immunostaining results suggest that small MFP tumours best replicate the
vascular permeability required to observe the EPR effect in vivo. A more predictable growth profile and the absence
of ulcerated skin lesions further point to the MFP model as a strong choice for long term treatment studies that
initiate after a target tumour size has been reached.
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Pre-clinical development of anti-cancer therapeutics re-
lies on availability of relevant and reproducible in vivo
tumour models. Human tumour xenograft models in
immunodeficient mice are widely used to assess pharma-
cokinetics, biodistribution, and treatment efficacy be-
cause they are inexpensive and easy to replicate [1].
However, their utility in evaluating potential treatment
strategies depends on their capacity to recapitulate
human disease conditions.
Progress in nanomedicine seeks to shift distribution of
therapeutic compounds to tumour tissue by targeting
hyperpermeable tumour vasculature [2,3]. Tumours are
restricted in size until they can trigger greater blood ves-
sel density through angiogenesis and blood vessel re-
modeling [4,5]. Compared to normal tissue, tumour
tissue has been demonstrated to be more permissive to
extravasation of macromolecules as a result of abnormal
blood vessel structure [3]. Moreover, tumour tissue is
subject to poor lymphatic drainage, leading to greater re-
tention of material in the extravascular space. These
combined phenomena are called enhanced permeability
and retention (EPR) and form the basis for improved se-
lectivity of nanoscale drug delivery for solid tumour tar-
geting [2,4,6].
Several pathological features of tumour vasculature
lead to its utility in targeting applications. Pathological
tumour vessels are dynamic, and can result both from
angiogenesis and remodeling of existing vessels [5,7].
Endothelial cells that comprise tumour blood vessels
have poor organization, leading to gaps between cells,
multiple endothelial cell layers, and unusual tortuosity
and branching [8,9]. These openings allow unregulated
movement of macromolecules and nanoscale carriers
across tumour vessel walls and into the surrounding tis-
sue [10]. In response, the associated basement mem-
brane is also often thickened or absent [9,11]. This
apparent dichotomy stems from a dynamic interaction
between increased and multilayered collagen deposition
in the basement membrane [10,12-14] and increased ex-
pression of matrix metalloproteinases (MMPs) that can
result in collagen degradation [15]. Further enhancing
the aberrant permeability of tumour blood vessels, the
pericytes that normally cover and stabilize the outer ves-
sel wall can also be missing or detached, leading to a
more immature vessel structure [5]. The absence of
these contractile support cells may lead to further
increased vessel permeability and weakened control over
blood flow [7]. Lymphatic vessels are closely associated
with and derived from the blood vessel network. They
are responsible for transporting waste out of tissues, but
tumours are often deficient in lymphatic drainage, lead-
ing to increased accumulation of macromolecular mater-
ial in tumour tissue [4]. Each of these featurescontributes to the pathophysiology that enables the EPR
effect. Vascular permeability factors, such as bradykinin
and nitric oxide, also mediate and enhance vascular
hyperpermeability [16]; however, our analysis will be
limited to physical vascular defects and their contribu-
tions to EPR.
To validate the use of human tumour xenografts in
mouse models of breast cancer to investigate tumour
targeting via EPR, we studied MDA-MB-231-H2N cells
transplanted in NOD scid gamma (NSG) mice and com-
pared two common cell injection sites in the context of
EPR permissive pathology. Owing to its simplicity,
tumour cells are often introduced ectopically as subcuta-
neous (SC) injections, regardless of their native tissue
type [17-19]. Cells injected orthotopically (eg. breast
cancer cells into mammary tissue) are subject to bio-
logical cues present in the relevant organ environment
[18]. Allowing tumour cells to grow in their orthotopic
environment influences growth rate, blood and lymph-
atic vessel development, metastatic potential, interstitial
pressure, and response to therapy [5,18-21]. We
hypothesized that the orthotopic environment may also
influence the permeability of the resulting tumour vas-
culature. Notably, to promote successful tumour engraft-
ment in both locations, our chosen cell line is known to
be tumourigenic in the absence of external factors, such
as estrogen [22]. Groups of animals were compared as
cohorts of matching tumour size because size, and not
elapsed time, is a standard prognostic measure used to
assess breast cancer stage [23].
Currently, the benefit of using either SC or MFP in
xenograft models of breast cancer in assessing targeting
through the EPR effect is not well characterized. To in-
vestigate vessel permeability, orthotopic and ectopic
tumour-bearing NSG mice were given intravenous injec-
tions of a fluorescently labeled high molecular weight
dextran (FITC-Dextran, 2 MDa, ~80 nm [8]) as a model
nanocarrier. After allowing the dextran to circulate, ani-
mals were sacrificed, their tumours removed, measured
using calipers, and fixed with paraformaldehyde.
Tumours were cryosectioned and examined for dextran
accumulation. Tissue sections were also immunostained
for markers of vascular endothelial cells (CD31), base-
ment membrane (collagen IV), pericytes (alpha smooth
muscle actin (αSMA)), and lymphatic vessels (lymphatic
vessel endothelial hyaluronan receptor (LYVE-1)).
Methods
Materials
All cell culture materials were purchased from Gibco-
Invitrogen (Burlington, ON, Canada). MDA-MB-231-
H2N cells and NOD scid gamma (NSG) mice were
generous gifts from Dr. Robert Kerbel (Sunnybrook
Research Institute, Toronto, ON, Canada), which were
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tran-FITC (MW 2 ± 0.2 MDa) was purchased from Invi-
trogen (Burlington, ON, Canada). Slides and cover slips
were purchased from Fisher Scientific (Ottawa, ON,
Canada). Primary antibodies were purchased from
Abcam (Cambridge, MA, USA) for CD31 (ab28364),
LYVE-1 (ab14917), collagen IV (ab19808), and αSMA
(ab5694). Immunostaining reagents (rabbit IgG Elite
ABC kit, avidin/biotin kit, enzyme substrates, Vecta-
shield mounting medium) were purchased from Vector
Labs (Burlington, ON, Canada). Entellan hard mounting
medium was purchased from EMD Millipore (Billerica,
MA, USA). All other materials were purchased from
Sigma-Aldrich (Mississauga, ON, Canada) and used as
received unless otherwise noted.
Cell maintenance and preparation
MDA-MB-231-H2N cells were maintained in RPMI
1640 culture medium, supplemented with 10% heat-
inactivated fetal bovine serum (FBS), 50 units/mL peni-
cillin and 50 mg/mL streptomycin under a humidified
5% CO2 environment. To prepare cell suspensions for
injection, adherent cells were first rinsed with phosphate
buffered saline, pH 7.4 (PBS), and then incubated briefly
with trypsin-ethylenediamine tetraacetic acid (trypsin-
EDTA, 0.25%/0.038%). Once the cells were suspended,
enzymatic digestion was inhibited with FBS, and the
cells were pelleted and washed 3 times in PBS before re-
suspension at the desired concentration. Cells were kept
on ice prior to injection.
Tumour xenograft models
The protocols used in these in vivo studies were
approved by the University Health Network Animal Care
Committee and performed in accordance with current
institutional and national regulations. Animals were
housed in a 12 h light and 12 h dark cycle with free
access to food and water. NSG mice were bred in-house,
and 7–9 week old female mice were selected for tumour
xenotransplantation.
Mice in all experimental groups were inoculated with
106 MDA-MB-231-H2N cells suspended in 50 μL of
sterile PBS. Prior to injection, mice were anaesthetized
with isoflurane-oxygen. To form ectopic SC tumours,
anaesthetized mice were injected with cells under the
skin in the right dorsal flank. To form orthotopic mam-
mary fat pad (MFP) tumours, the surgical area was depi-
lated and swabbed with 70% ethanol and betadine before
making an incision in the skin of the lower abdomen to
the right of the midline, uncovering the mammary
fat pad in the right inguinal region where cells were
injected into the fat pad. The incision was then sutured
closed and lactated Ringer’s solution and buprenor-
phine were given post-operatively for recovery and painmanagement. Solid tumours were allowed to form over
a period of 3–5 weeks. Cohorts of tumour-bearing ani-
mals were divided into two groups to proceed onwards
for testing; the first group was tested once their tumours
reached an average diameter along the major axis of
7 mm as measured through the skin using calipers, and
the second group tested the following week.Dye injections and tissue collection
Once tumours reached their target size, mice were
injected with 0.5 mg of FITC-dextran in 200 μL of PBS
via intravenous (IV) tail vein injection [8]. After 1 h, ani-
mals were sacrificed by CO2 asphyxiation and tissue
samples (tumour and liver) were collected by dissection;
tumour samples were directly measured for diameter
along both the major and minor axes (L and W) and
thickness (H) using calipers (ellipsoid volume calculated
as π/6 × L ×W ×H [24]), and each sample was placed
separately in cassettes and submerged in 4% paraformal-
dehyde for 24 h at 4°C. Tissue samples were then cryo-
protected in 30% sucrose in PBS and stored at 4°C.
Tissue samples were cryosectioned in 10 μm sections,
and pairs of slices 50 μm apart were mounted onto
slides, and stored at −80°C. For fluorescence analysis,
slides were rehydrated in PBS and coverslipped using
Vectashield mounting medium.Immunostaining
Three slides (six tissue sections) from each tumour were
selected for each set of stains such that each slide con-
tained sections a minimum of 300 μm away from the
previous slide. Thawed slides were hydrated and washed
in PBS and incubated with 0.3% H2O2 in methanol for
20 min before being washed in PBS again and blocked in
1.5% normal goat serum (NGS) in PBS (see Table 1 for
details). Avidin and biotin blocking reagents were ap-
plied sequentially for 15 min each before incubating with
the primary antibody at 4°C overnight (dilutions noted
in Table 1). The following day, slides were washed in
PBS and incubated with a biotinylated secondary goat
anti-rabbit IgG (1:200 dilution as instructed in kit), fol-
lowed by incubation with avidin-biotinylated enzyme
complex (ABC reagent) (times noted in Table 1). Rinsed
sections were then developed using 3,3’-diaminobenzi-
dine (DAB) enzyme substrate for 1–10 min (brown
product). If applicable, slides were then co-stained by
repeating the above procedure beginning at the NGS
blocking step, and developed in VIP enzyme substrate
for 5–7 min (violet product). All slides were counter
stained by applying 0.5% methyl green for 10 min (blue-
green nuclear stain), washed in distilled water, dried in
1-butanol, and transferred to xylene before being cover-
slipped using Entellan hard mounting medium.
Table 1 Immunostaining protocol details listed by antigen
CD31 Collagen IV αSMA LYVE-1
NGS blocking incubation time 1 h 1 h 1 h 20 min
Primary antibody dilution 1:200 1:1000 1:1000 1:1000
Secondary antibody incubation time 1 h 30 min 30 min 30 min




















Figure 1 MFP and SC tumour sizes. Tumour volumes were
calculated based on caliper measurements post-dissection of the
major and minor axes and thickness (n = 4–6). SC tumours required
longer development times to become size matched to MFP
tumours. Greater variability was also observed at longer times,
particularly in SC tumours, where several animals had smaller
tumours than the cohort examined the week before.
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All fluorescence images (FITC-dextran) were acquired
with a fixed exposure time for each channel using an
Olympus BX50 with a UPlanSApo 10×/0.40 objective,
Photometrics CoolSNAP HQ2 monochrome camera,
and motorized stage (Olympus Canada Inc., Richmond
Hill, ON, Canada). Images were tiled together using
Metamorph, and analyzed using ImageJ. To compensate
for blood remaining in tissue after sacrifice, the blood-
associated fluorescence intensity was quantified in hep-
atic sinusoids in liver tissue slices. Pixels matching this
intensity were subtracted from the positive pixel count
in the subsequent analysis.
Brightfield images (immunostaining) were acquired
using an Aperio ScanScope XT (Aperio, Vista, CA,
USA) for whole slide scanning at 20× magnification and
analyzed using ImageScope Microvessel Analysis. Statis-
tical significance between groups was first tested with
Bartlett’s test for equality of variance (P < 0.05). Where
variances were equivalent, one-way ANOVA was ap-
plied, followed by a corrected unpaired t-test; differences
are denoted by square bracket symbols connecting the
differing groups (P < 0.05, unless otherwise noted).
Results and discussion
Orthotopic cell transplantation influences tumour growth
rate and size variation
Tumour size of human tumour xenograft models grown
in mice both orthotopically (MFP) and ectopically (SC)
was monitored weekly through the skin in live animals
using calipers. Following cell injection, MFP tumours
reached a target size of 7 mm in diameter across the
major axis by 3 weeks post-injection whereas SC
tumours took an additional 2 weeks to reach this size.
Differences in growth rate were expected, as each injec-
tion site provides a different microenvironment. Cohorts
of animals were selected based on tumour size matching
instead of development time because size is one of three
standard measurements that determines breast cancer
prognosis [23]. After resection, tumours were measured
directly using calipers and the volumes were calculated
based on measurements of the major and minor axes
and thickness (Figure 1). The difference in time needed
to achieve size matched populations for MFP and SC
tumour models suggests that the organ environment
influences the growth rate of xenografted cells.To investigate effects associated with tumour size, 4
animals from each tumour type were randomly selected
for dextran injection and tumour resection once the
7 mm major axis diameter was reached, with the
remaining animals evaluated the following week. The
7 mm target size was selected to allow adequate vascular
pathology to develop, as neovascularization of the
tumour is most pronounced over serveral days immedi-
ately after a palpable mass (20 mm3) has formed [25].
Notably, the week after this target size was reached,
tumour size variability increased in both tumour sites (P
< 0.05 by Bartlett’s test of equality of variances). Unex-
pectedly, several tumours in the SC group at 6 weeks
post-cell injection were smaller than those observed the
previous week (Figure 1). Additionally, several replicates
were of similar size or larger size, resulting in a broad
size distribution of the resulting tumours. In this group,
4 out of 6 animals developed hard fibrotic tissue leading
to an ulcerated skin lesion by this time (an indication for
humane sacrifice). These lesions, which made these ani-
mals unsuitable for further study beyond this time, were
not observed in any other group. MFP tumours were
grown from cells injected directly into the centre of the
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contact with the skin, which may have prevented ulcer-
ation. These injected cells also had access to the pre-
existing vascular network and biological signaling mole-
cules present in the MFP. Overall, the MFP tumours
were more consistent in size than the SC tumours.
Given that the cell line (MDA-MB-231-H2N) and mouse
strain (NSG) that we selected are well-established as
highly permissive to tumour xenografts [22,26], we ex-
pect trends to be similar using other combinations of
cells and mice. However, it is possible that other systems
will behave differently. Given the large variability in the
6 week SC tumour group, these samples were not fur-
ther analyzed. Instead, 5 week SC tumours were com-
pared with 3 and 4 week MFP tumours, which were
similar in size.0
MFP 3 wks MFP 4 wks SC 5 wks
Figure 2 FITC-Dextran accumulation in tumour tissue
normalized to liver tissue control. High molecular weight dextran
(2 MDa, ~80 nm) was injected IV into tumour animals as a model
nanocarrier and allowed to distribute prior to sacrifice. 3 week old
MFP tumours showed higher accumulation of the nanocarrier than
5 week old SC tumours at a 90% confidence interval. All data are
shown as the mean of n = 4 animals ± SD. Lines connecting bars
denote statistical significance, P < 0.10.MFP tumours exceed SC tumours in model nanocarrier
accumulation
Prior to sacrifice, a high molecular weight FITC-dextran,
used as a model nanocarrier, was injected to assess blood
vessel permeability. Data were normalized to liver
tissue collected as a positive control: liver endothelial
cells have natural fenestrations (123 ± 24 nm diameter)
[27] for transfer of substrates from the blood to hepa-
tocytes, making the liver an ideal organ for observing
nanocarrier uptake. In mice, blood flow through the
liver is also estimated at 23% of cardiac output, mak-
ing it one of the best perfused organs on a per gram
basis [28].
Based on fluorescence images of tissue sections, rela-
tively poor dextran uptake was observed in tumour tis-
sue compared to liver tissue across all groups. A
threshold was defined to exclude background signal
detected in blank tumour and liver tissue and the
remaining areas, representing levels above this threshold,
were quantified. Less than 1% of the positive signal area
observed in the liver control was observed in tumour
slices (Figure 2). This can partially be explained by rela-
tively low blood flow through tumour tissue, which has
previously been reported to be up to 5-fold lower than
in liver [29]. The remaining discrepancy between the
dextran accumulation between tumour and liver samples
suggests that the model tumour vasculature was less
permissive to dextran uptake than the fenestrated liver
endothelium, and/or that the lymphatic drainage in the
model tumour prevented stable dextran accumulation.
Interestingly, dextran uptake in 3 week old MFP
tumours was higher than size matched 5 week old SC
tumours at 90% confidence (P = 0.08 by one-way
ANOVA), suggesting that the orthotopic MFP environ-
ment encouraged EPR permissive vasculature and/or
lymphovasculature.Elements of tumour vascular pathophysiology observed
in tumour models
To better understand the underlying vascular patho-
physiology present in both tumour models, tumour
slices were immunostained to provide information on
the blood and lymphatic vessels present. Tissue was
stained for CD31, an endothelial cell marker, to locate
and characterize blood vessels. In normal blood vessels,
an intact monolayer of endothelials cells is expected,
whereas hyperpermeable tumour blood vessels are char-
acterized by multiple layers of discontinuous endothelial
cells that may sprout outwards or project into the vessel
lumen [10,13]. The CD31 staining revealed greater vessel
wall thickness across all groups when compared to liver
tissue (represented by a dashed line) which was used as
a healthy tissue control (Figure 3A). This observation
suggests that blood vessels present in all models,
whether they are existing vessels that have been remod-
eled or newly formed vessels, have the abnormal multi-
layered endothelial cell structure associated with solid
tumours. The vessel thickness was highest in the 3 week
old MFP tumours, indicating a greater level of endothe-
lial cell disorganization in this group. It is possible that
this led to the increased permeability observed in the
3 week MFP tumours using a relatively large model

































































































Figure 3 CD31 and collagen IV immunostaining. Mean blood vessel wall thickness visualized through A CD31 (endothelial cells) and B
collagen IV (basement membrane). Both are abnormally thick as compared to healthy liver control tissue, which is denoted by the dashed line. C
shows that mean blood vessel density assayed using CD31 staining is greatest in 3 week old MFP tumours. D indicates mean vascular area as a
measure of blood vessel size and capacity. Their small size categorizes them as microvasculature. All data are shown as the mean of n = 4
animals ± SD. Starred lines connecting bars denote statistical significance, P < 0.05.
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(~7 nm) [30,31].
Separate sections were also co-stained for collagen IV
to visualize the thickness of the associated basement
membrane. The basement membrane forms a physical
barrier that inhibits transport of high molecular weight
materials across blood vessel walls [15,32]. In tumour
pathophysiology, opposing phenomena have been
observed: the basement membrane can thicken, thin, or
even be absent. In the MFP and SC tumour models, the
basement membrane was thickened compared to healthy
liver blood vessels (Figure 3B). This observation is con-
sistent with the xenografted MDA-MB-231-H2N cell
line being poorly invasive like its parental line, MDA-
MB-231 [33]. Conversely, a more metastatic cell line is
often capable of using MMPs to degrade the basement
membrane to enable cell migration through neighbour-
ing blood vessels [33]. The 5 week old SC tumours were
observed to have the highest basement membrane thick-
ness, indicating the greatest mass transport barrier
against nanocarrier delivery.CD31 staining also revealed differences in vascular
density, with the 3 week old MFP tumours having a
significantly greater vessel density than the other groups
(Figure 3C). The decrease in vascular density from
3 weeks to 4 weeks in the MFP model suggests that
the tumour cell growth may be too rapid for the cor-
responding new blood vessels to form. The thick base-
ment membranes observed in the tumour tissue may
also contribute to this deficiency as the basement mem-
brane must be degraded before vascular branching can
occur [15]. Although the 3 week old MFP and 5 week
old SC tumours were size matched, the MFP model
had greater blood vessel density, which may be attribu-
ted to greater vascular density in the MFP. Together
these observations suggest that remodeling blood vessels
already present in the transplantation site are import-
ant in establishing relevant tumour vasculature. The
relatively poor vascular density in SC tumours may
also explain the poor engraftment after 6 weeks, as a
lack of blood flow may inhibit further growth and lead
to necrosis.
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indication of the size, and therefore the capacity of the
blood vessels present in each tumour type. The vascular
area in 3 week old MFP tumours was significantly higher
than the 4 week old MFP tumours (Figure 3D), indicat-
ing that in addition to decreasing vessel density with in-
creasing tumour size, there is on average a lower
capacity for blood in the vessels present. Having a
greater density and capacity for blood perfusion
enhances the likelihood for delivery of materials to the
3 week old MFP tumours through systemic circulation.
At the same time, all of the evaluated models are likely
underperfused as their small size categorizes them as
microvasculature [34]. This low overall capacity for
blood flow impacts their utility in assessing nanocarrier
accumulation via EPR, and likely results in regions of
hypoxia and heterogeneous drug distribution.
CD31 was also co-stained with αSMA to visualize dif-
ferences in pericyte association with blood vessels. Peri-
cytes are important blood vessel support cells that help
to regulate blood flow and vessel permeability, but are
often detached in tumour pathophysiology. The
observed staining patterns suggest that this was the case
across all tumour models (Figure 4A-C). Pericytes (vio-
let) were distributed throughout tumour tissue instead
of associating exclusively with blood vessels (brown) and
forming uniform layers around the endothelial cell layer,
as observed in healthy liver tissue (Figure 4D).
LYVE-1 staining was used to detect lymphatic vessels
in tumour tissue. Lymphatic vessels provide a networkA
C
Figure 4 CD31 and αSMA co-staining. Representative images of pericyte
brown) in: A 3 week MFP, B 4 week MFP, and C 5 week SC tumours. Sever
represents cell nuclei. D shows that pericytes are exclusively associated wit
200 μm.to drain protein rich interstitial fluid back into circula-
tion. By the nature of their function, these vessels are
porous to allow macromolecules to be transported [35],
and therefore nanocarrier accumulation in tumour tissue
may increase when their expression is impaired. Mouse
models of lymphatic impairment can be generated by
surgically ablating lymphatic vessels in the tail, resulting
in lymphedema. In these models, the surrounding tissue
attempts to restore homeostasis by generating new
lymphatic vessels and dilating the remaining lymphatic
vessels, suggesting that both density and diameter im-
pact drainage capacity [36]. LYVE-1 stained sections
were used to quantify lymphatic vessel size and density
(Figure 5A-B). Both of these measures gave different var-
iances between groups (P < 0.05 by Bartlett’s test of equal-
ity of variances) meaning that the groups tested were not
equivalent. While the mean lymphatic vessel density was
highest in the 3 week old MFP tumours, the 5 week old
SC tumours demonstrated the highest mean lymphatic
vessel area. These factors counterbalance one another, as
density and capacity each contribute to overall drainage.
There is evidence that both the MFP and SC tumour
models yielded poor lymphatic drainage compared to
healthy tissue. Accumulation of interstitial fluid in cases
of lymphedema has been shown to lead to the deposition
of collagen [37]. Visual examination of the tumour slices
revealed a high density of collagen IV-lined spaces
that were CD31 negative, which likely represent fluid-
filled cavities in the tumour tissue (Figure 5C-D). These
likely contain excess interstitial fluid resulting from aB
D
s (αSMA, violet) that are not associated with blood vessels (CD31,
al blood vessels are highlighted with black arrows; blue staining












































Figure 5 LYVE-1 immunostaining. A shows mean lymphatic vessel density, and B shows mean vessel area, both of which are indicators of
lymphovascular capacity. Both measures were found to have unequal variance between groups, and therefore although the groups were not
equivalent, ANOVA could not be used to verify their differences. While 3 week old MFP tumours had the highest mean lymphatic vessel density,
5 week old SC tumours had greater mean vessel size, both of which contribute to overall lymphatic drainage capacity. All data are shown as the
mean of n = 4 animals ± SD. Representative images of fluid-filled spaces lined with collagen (violet) but not with endothelial cells (negative for
CD31, brown)are shown in: C 3 week MFP and D 5 week SC tumours. Several of these spaces, which indicate lymphedema, are highlighted with
black arrows; blue staining represents cell nuclei. Scale bars represent 200 μm.
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cient lymphatic drainage.
Taken together, the data gathered through CD31 and
collagen IV immunostaining suggest that, of the models
tested, the 3 week MFP tumour best replicates the vas-
cular permeability required to observe the EPR effect
in vivo. However, the blood vessels visualized are sparse
and small, contributing to low accumulation of the
model nanocarrier used in this study. Both MFP and SC
tumours showed evidence of excess interstitial fluid ac-
cumulation, suggesting poor lymphatic drainage in both
models. While MFP tumours demonstrated greater
lymphatic vessel density, SC tumours had greater lymph-
atic vessel size, both of which contribute to drainage,
making it difficult to easily differentiate the two models
in terms of drainage capacity. MFP tumours demon-
strated greater utility for long-term treatment studies, as
their growth is more consistent at large tumour sizes,
and no skin ulcerations were observed.
Conclusions
This study provides insight into the vascular properties
of human tumour xenograft models of breast cancer inboth MFP (orthotopic) and SC (ectopic) environments,
two common pre-clinical models. When both animal
models were challenged with a high molecular weight
dextran as a model nanocarrier, there was higher accumu-
lation in MFP tumours 3 weeks after cell injection. Fur-
ther adding to the evidence that MFP tumour vasculature
has greater permeability to macromolecules – a patho-
logical feature relevant to nanocarrier accumulation via
EPR – CD31 and collagen IV immunostaining revealed
greater vascular density and size, as well as thinner base-
ment membranes, in MFP tumours collected 3 weeks
after cell injection. Both models demonstrated poor dex-
tran accumulation compared to the liver as a positive
control, suggesting that although several pathological fea-
tures were observed, low vascular density and small blood
vessel size led to relatively poor tumour perfusion. Both
the MFP and SC tumour models showed evidence of poor
lymphatic drainage, as several CD31 negative and collagen
IV-lined fluid-filled cavities were observed. The MFP
environment offered several practical benefits, including
shorter development times to reach a target tumour size,
more consistent growth profiles, and the absence of ulcer-
ated skin lesions observed in SC tumour animals.
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